Orion Oyj engages in the development and manufacture of pharmaceuticals and active pharmaceutical ingredients (APIs) worldwide.
Flawless balance sheet with proven track record.
Share Price & News
How has Orion Oyj's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ORNAV has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ORNAV exceeded the Finnish Pharmaceuticals industry which returned 17.4% over the past year.
Return vs Market: ORNAV exceeded the Finnish Market which returned 10.1% over the past year.
Price Volatility Vs. Market
How volatile is Orion Oyj's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Orion Oyj undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ORNAV (€37.8) is trading above our estimate of fair value (€36.43)
Significantly Below Fair Value: ORNAV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ORNAV is poor value based on its PE Ratio (27.1x) compared to the Pharmaceuticals industry average (25.8x).
PE vs Market: ORNAV is poor value based on its PE Ratio (27.1x) compared to the Finnish market (21.6x).
Price to Earnings Growth Ratio
PEG Ratio: ORNAV is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: ORNAV is overvalued based on its PB Ratio (7x) compared to the XE Pharmaceuticals industry average (3.1x).
How is Orion Oyj forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORNAV's forecast earnings growth (7.9% per year) is above the savings rate (-0.1%).
Earnings vs Market: ORNAV's earnings (7.9% per year) are forecast to grow slower than the Finnish market (10% per year).
High Growth Earnings: ORNAV's earnings are forecast to grow, but not significantly.
Revenue vs Market: ORNAV's revenue (3.5% per year) is forecast to grow faster than the Finnish market (-0% per year).
High Growth Revenue: ORNAV's revenue (3.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORNAV's Return on Equity is forecast to be high in 3 years time (29.6%)
How has Orion Oyj performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORNAV has high quality earnings.
Growing Profit Margin: ORNAV's current net profit margins (19.1%) are lower than last year (20.2%).
Past Earnings Growth Analysis
Earnings Trend: ORNAV's earnings have declined by -2.6% per year over the past 5 years.
Accelerating Growth: ORNAV's earnings growth over the past year (1.5%) exceeds its 5-year average (-2.6% per year).
Earnings vs Industry: ORNAV earnings growth over the past year (1.5%) exceeded the Pharmaceuticals industry -5%.
Return on Equity
High ROE: ORNAV's Return on Equity (25.7%) is considered high.
Return on Assets
Return on Capital Employed
How is Orion Oyj's financial position?
Financial Position Analysis
Short Term Liabilities: ORNAV's short term assets (€600.1M) exceed its short term liabilities (€187.5M).
Long Term Liabilities: ORNAV's short term assets (€600.1M) exceed its long term liabilities (€68.8M).
Debt to Equity History and Analysis
Debt Level: ORNAV's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: ORNAV's debt to equity ratio has reduced from 45.3% to 0.3% over the past 5 years.
Debt Coverage: ORNAV's debt is well covered by operating cash flow (11773.9%).
Interest Coverage: ORNAV's interest payments on its debt are well covered by EBIT (133.1x coverage).
Inventory Level: ORNAV has a high level of physical assets or inventory.
Debt Coverage by Assets: ORNAV's debt is covered by short term assets (assets are 260.9x debt).
What is Orion Oyj's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Orion Oyj before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: ORNAV's dividend (3.89%) is higher than the bottom 25% of dividend payers in the Finnish market (2.07%).
High Dividend: ORNAV's dividend (3.89%) is low compared to the top 25% of dividend payers in the Finnish market (4.47%).
Stability and Growth of Payments
Stable Dividend: ORNAV's dividends per share have been stable in the past 10 years.
Growing Dividend: ORNAV's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (105.2%), ORNAV's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ORNAV's dividends in 3 years are not forecast to be well covered by earnings (97.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Timo Lappalainen (57yo)
Mr. Timo Lappalainen, M.Sc. (Ind. Eng.), has been the Chief Executive Officer and President of Orion Oyj (Formerly, Orion Corporation) since January 2008. Mr. Lappalainen has been the Chairman of the Execu ...
CEO Compensation Analysis
Compensation vs Market: Timo's total compensation ($USD1.46M) is about average for companies of similar size in the Finnish market ($USD1.16M).
Compensation vs Earnings: Timo's compensation has been consistent with company performance over the past year.
|CEO, President & Chairman of the Executive Management Board||12.1yrs||€1.35m||0.075% €4.1m|
|CFO, Senior VP of Animal Health & Member of the Executive Management Board||17.5yrs||no data||0.020% €1.1m|
|Senior VP of Corporate Functions||0yrs||no data||0.039% €2.1m|
|Senior VP of Growth Projects & Member of Executive Management Board||0yrs||no data||0.019% €1.1m|
|Senior VP of Commercial Operations and Member of the Executive Management Board||12.1yrs||no data||0.019% €1.0m|
|Senior VP of Supply Chain & Member of the Executive Management Board||0yrs||no data||0.019% €1.0m|
|Senior VP of Specialty Products & Member of Executive Management Board||8.1yrs||no data||0.014% €747.4k|
|Employee Representative Executive Management Board||0yrs||no data||no data|
|Senior VP of Research & Development and Member of Executive Management Board||3yrs||no data||0.0030% €162.1k|
|Investor Relations & Financial Communications Officer||0yrs||no data||no data|
Experienced Management: ORNAV's management team is seasoned and experienced (12.1 years average tenure).
|Independent Director||5.9yrs||€62.67k||0.0039% €214.1k|
|Vice Chairman||3.9yrs||€79.65k||0.019% €1.1m|
|Independent Director||2.9yrs||€57.27k||0.00072% €39.4k|
|Independent Director||0.9yrs||no data||no data|
|Independent Director||3.9yrs||€57.27k||0.0078% €429.3k|
|Independent Director||2.9yrs||€56.67k||0.0027% €148.4k|
Experienced Board: ORNAV's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Orion Oyj's company bio, employee growth, exchange listings and data sources
- Name: Orion Oyj
- Ticker: ORNAV
- Exchange: HLSE
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €5.476b
- Shares outstanding: 140.49m
- Website: https://www.orion.fi
Number of Employees
- Orion Oyj
- Orionintie 1A
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORNAV||HLSE (OMX Nordic Exchange Helsinki)||Class A Shares||FI||EUR||Jul 2006|
|ORNBV||HLSE (OMX Nordic Exchange Helsinki)||Yes||Class B Shares||FI||EUR||Jul 2006|
|OFK||DB (Deutsche Boerse AG)||Yes||Class B Shares||DE||EUR||Jul 2006|
|0M2N||LSE (London Stock Exchange)||Class A Shares||GB||EUR||Jul 2006|
|0M2O||LSE (London Stock Exchange)||Yes||Class B Shares||GB||EUR||Jul 2006|
|ORIN.F||OTCPK (Pink Sheets LLC)||Yes||Class B Shares||US||USD||Jul 2006|
|ORNBVH||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Class B Shares||GB||EUR||Jul 2006|
|ORNAVH||BATS-CHIXE (BATS 'Chi-X Europe')||Class A Shares||GB||EUR||Jul 2006|
|ORIN.Y||OTCPK (Pink Sheets LLC)||ADR||US||USD||Apr 2010|
Orion Oyj engages in the development and manufacture of pharmaceuticals and active pharmaceutical ingredients (APIs) worldwide. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson’s disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has research collaboration with Fifth Corner Inc. to seek solutions to improve the quality of life of prostate cancer patients. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, and laboratories. Orion Oyj is headquartered in Espoo, Finland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 21:17|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.